Passage Bio Reports Q1 2025 Financial Results and Updates

An update from Passage Bio ( (PASG) ) is now available.

On May 13, 2025, Passage Bio reported its first quarter 2025 financial results and business highlights. The company made significant progress in its upliFT-D trial for PBFT02, treating the first FTD-GRN patient with a new dose and enrolling a second patient, with more being evaluated. They also presented a new manufacturing process at the ASGCT meeting, which could enhance productivity and purity. Financially, Passage Bio reported a net loss of $15.4 million for the quarter, with a cash runway extending into the first quarter of 2027.

The most recent analyst rating on (PASG) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.

Spark’s Take on PASG Stock

According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.

Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.

To see Spark’s full report on PASG stock, click here.

More about Passage Bio

Passage Bio is a clinical stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases. Their lead product candidate, PBFT02, aims to treat conditions like frontotemporal dementia by increasing progranulin levels to restore lysosomal function and slow disease progression.

Average Trading Volume: 181,902

Technical Sentiment Signal: Sell

Current Market Cap: $19.16M

For an in-depth examination of PASG stock, go to TipRanks’ Stock Analysis page.